The use of phosphodiesterase 5 inhibitors with concomitant medications
Authors:
- 1 September 2008
- journal article
- review article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 31 (9) , 799-808
Abstract
The phosphodiesterase-5 inhibitors (PDE5i) sildenafil, vardenafil, and tadalafil are considered first-line therapy for the treatment of patients with erectile dysfunction (ED). In addition to the classical pro-erectile-effect, clinical findings have suggested that they can also influence vascular tone in pulmonary, coronary and other vascular tissues, as well as improving symptoms associated with benign prostatic hyperplasia. Therefore, considering the hypothetical widespread application of PDE5i, the potential for drug-drug interactions emerges as a relevant factor in determining the safety profile of PDE5i. Review of relevant literature was conducted using data sources from MEDLINE (1998, to June 2007). The use of nitrates remains the only contraindication for all 3 PDE5i. Vardenafil is also not recommended in patients taking type 1A (such as quinidine, or procainamide) or type 3 antiarrhythmics (such as sotalol, or amiodarone) while no other major limitations have been reported for tadalafil and sildenafil. In contrast to previously reported labeling, recent studies have suggested only a precaution, but not contraindication with the concomitant use of α-blockers agents. In addition, precaution is also suggested in the presence of potent CYP3A inhibitors, such as azole antifungals, antiretroviral protease inhibitors, or macrolid antibiotics. This is because sildenafil, vardenafil, and tadalafil are metabolized mainly via the CYP3A4 pathway. On the other hand, statins and testosterone seem to have synergic effects with PDE5i on sexual activity.Keywords
This publication has 78 references indexed in Scilit:
- Type 5 Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction and Cardiovascular DiseaseCardiology in Review, 2007
- Assessment of the Relational Factor in Male Patients Consulting for Sexual Dysfunction: The Concept of Couple Sexual DysfunctionJournal of Andrology, 2006
- Combining Testosterone and PDE5 Inhibitors in Erectile Dysfunction: Basic Rationale and Clinical EvidencesEuropean Urology, 2006
- Psycho‐Biological Correlates of Free‐Floating Anxiety Symptoms in Male Patients With Sexual DysfunctionsJournal of Andrology, 2006
- Pharmacology and Drug Interaction Effects of the Phosphodiesterase 5 Inhibitors: Focus on α-Blocker InteractionsThe American Journal of Cardiology, 2005
- Cardiac Safety in Clinical Trials of Phosphodiesterase 5 InhibitorsThe American Journal of Cardiology, 2005
- Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile DysfunctionCirculation, 2004
- RANDOMIZED STUDY OF TESTOSTERONE GEL AS ADJUNCTIVE THERAPY TO SILDENAFIL IN HYPOGONADAL MEN WITH ERECTILE DYSFUNCTION WHO DO NOT RESPOND TO SILDENAFIL ALONEJournal of Urology, 2004
- Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panelThe American Journal of Cardiology, 2000
- Regulation of the mevalonate pathwayNature, 1990